 |
|
Women may stop anticoagulants after blood clots
August 26, 2008Women may safely discontinue oral anticoagulants (blood thinners) after 6 months of treatment following a first unprovoked venous blood clot (thromboembolism) if they have no or one risk factor, concludes a study of 646 participants in a multicentre prospective cohort study http://www.cmaj.ca/press/pg417.pdf.
Blood clots are common and a potentially fatal condition. For patients with spontaneous blood clots who stop anticoagulation therapy, the risk of a recurrence in the first year is 5% to 27%, yet there is a risk of major bleeding and fatal hemorrhage while continuing anticoagulants.
"It may be safe for women who have taken oral anticoagulants for 5-7 months after an unprovoked venous thromboembolism to discontinue therapy if they have 0 or 1 of the following: 1) hyperpigmentation (brown discoloration), edema (swelling) or redness of either leg; 2) a D-dimer level (blood clotting test) of 250ug/L or more while taking warfarin, 3) BMI [body mass index] 30kg/m2; and aged 65 years or more," conclude Dr. Marc Rodger and coauthors.
The authors caution that "it appears all men are at high risk of recurrence" and further investigation into risk determination needs to be pursued.
In an accompanying commentary http://www.cmaj.ca/press/pg401.pdf, Dr. Clive Kearon (Dr. Clive Kearon, Hamilton Health Sciences, 905-383-2251, kearonc@mcmaster.ca) states that patient preference for the duration of anticoagulant therapy must be considered in deciding whether to continue or discontinue therapy.
Canadian Medical Association Journal
The authors caution that "it appears all men are at high risk of recurrence" and further investigation into risk determination needs to be pursued.
In an accompanying commentary http://www.cmaj.ca/press/pg401.pdf, Dr. Clive Kearon (Dr. Clive Kearon, Hamilton Health Sciences, 905-383-2251, kearonc@mcmaster.ca) states that patient preference for the duration of anticoagulant therapy must be considered in deciding whether to continue or discontinue therapy.
Canadian Medical Association Journal
Anticoagulants Current Events and Anticoagulants News RSSStudy Investigates Non-Surgical Placement of a Gore-tex Type Device in the Heart to Stop Recurrent Strokes and Mini-Strokes
A study is under way at Rush University Medical Center using a small, soft-patch device made of a Gore-tex-type material - often used to make durable outerwear - to close a common hole found in the heart called a patent foramen ovale (PFO) in order to prevent recurrent strokes and transient ischemic attacks (TIAs) in adults.
Statins may prevent miscarriages
Hospital for Special Surgery researchers have found that statins may be able to prevent miscarriages in women who are suffering from pregnancy complications caused by antiphospholipid syndrome (APS), according to a study in mice.
Safety of antithrombotic treatment in acute coronary syndromes
The management of acute coronary syndromes (with or without ST segment elevation) requires the use of anticoagulants, antiplatelet agents (aspirin, clopidogrel and/or glycoprotein (GP) IIb/IIIa inhibitors), beta-blockers, thrombolytics in some cases, and revascularization / reperfusion.
Researchers design model for automated, wearable artificial kidney
Two researchers from UCLA and the Veterans Affairs Greater Los Angeles Healthcare System have developed a design for an automated, wearable artificial kidney, or AWAK, that avoids the complications patients often suffer with traditional dialysis.
New blood clot guidelines for pregnant women
New evidence-based guidelines address the prevention and management of thrombosis in key patient populations and reinforce recommendations related to the routine use of preventive therapies.
Computers as safe as medical experts for prescribing blood thinning drugs
The largest ever study into the administration of blood thinning drugs, principally Warfarin, has concluded that dosages calculated by computer are at least as safe and reliable as those provided by expert medical professionals.
Avoiding Spleen Removal for Cooley's Anemia Sufferers
Researchers from Weill Cornell Medical College may have discovered the precise role of a gene in one of the world's most common blood disorders, beta-thalassemia, commonly known as Cooley's anemia.
Are blood thinners post-op killers?
New study shows that the use of powerful anticoagulants to prevent pulmonary embolism may actually lead to more deaths after surgery
Comparison of anticoagulants for angioplasty show similar outcomes
In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within 8 months than patients who received uncoated stents.
Scripps scientists studying sepsis in mice find potential drug targets for deadly disease
"We have identified a key connection of signaling pathways in the cascade of events leading to sepsis. This defines a crucial point where the immune system spirals out of control to cause severe sepsis and where there is an opportunity for therapeutic intervention," says Scripps Research Professor Wolfram Ruf, who led the research with his postdoctoral fellow Frank Niessen.
More Anticoagulants Current Events and Anticoagulants News Articles
 | Blood, Coagulants and Anticoagulants to Cardiovascular Agents, Volume 4, Encyclopedia of Chemical Technology, 3rd Edition by Kirk Othmer |
 | Anticoagulants, Antiplatelets, and Thrombolytics (Methods in Molecular Medicine) 1This collection of review articles highlights the latest development of antithrombotics and provides proven experimental methods for the further development of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as the hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP... |
| Anticoagulants/ Antiplatelet Therapy and Cardiovascular Disease (Cardiology Clinics, 12:3) | |
| UAMS joins national test for drug to treat stroke. (University of Arkansas for Medical Science; anticoagulant Ancrod): An article from: Arkansas Business by Jim Harris This digital document is an article from Arkansas Business, published by Journal Publishing, Inc. on November 21, 1994. The length of the article is 1164 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
 | The 2007-2012 Outlook for Anticoagulant Pharmaceutical Preparations in Japan by Philip M. Parker This study covers the latent demand outlook for anticoagulant pharmaceutical preparations across the prefectures and cities of Japan. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,000 cities in Japan. For each city in question, the percent share the city is of it’s prefecture and of Japan is reported. These comparative... |
| Lifelong anticoagulant Tx warranted for APS.(Cardiovascular Medicine)(antiphospholipid syndrome): An article from: Internal Medicine News by Jeff Evans This digital document is an article from Internal Medicine News, published by International Medical News Group on October 1, 2004. The length of the article is 818 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web... | |
 | The 2007-2012 Outlook for Anticoagulant Pharmaceutical Preparations in Greater China by Philip M. Parker This study covers the latent demand outlook for anticoagulant pharmaceutical preparations across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as “regions”).... |
| Clinical Anticoagulant Therapy by I Myron Vigran, Irving S. Wright | |
| Guide to anticoagulant therapy: Management of heparin & warfarin by Joseph S Alpert | |
| A History of Anticoagulants: A Symposium. by IRVING S. (ed.) WRIGHT |
| © 2008 BrightSurf.com |